Anti-Angiogenic Treatment with Linomide as Adjuvant to Surgical Castration in Experimental Prostate Cancer
- 1 September 1997
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 158 (3) , 902-907
- https://doi.org/10.1016/s0022-5347(01)64361-1
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancersThe Prostate, 1995
- Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?European Journal Of Cancer, 1994
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- Predictors of pathologic stage in prostatic carcinoma. The role of neovascularityCancer, 1994
- The quinoline-3-carboxamide Linomide inhibits angiogenesis in vivoCancer Chemotherapy and Pharmacology, 1994
- Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast CarcinomaJNCI Journal of the National Cancer Institute, 1992
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric studyThe Journal of Pathology, 1992
- Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic CancerJournal of Urology, 1992
- The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancerThe Prostate, 1984